OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

Localised prostate cancer, very low and low risk: lines of therapy

Cancer page →

3 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Screening, prevention and diagnosis1·
Early / localised·2

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersDiagnosisMRI before biopsy and targeted plus systematic cores; genomic classifiers or AI pathology to refine surveillance decisions.
Multiparametric prostate MRI (PI-RADS)PRECISIONDecipher ProstateArteraAI Prostate
76

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupVery low and low risk, preferredActive surveillance with PSA every six months, MRI and repeat biopsy; treatment only on progression to Grade Group 2 or more.
Active surveillanceProtecTMultiparametric prostate MRI (PI-RADS)PSA (prostate-specific antigen)Gleason score / Grade Group
64
Risk groupLow risk, men who prefer treatmentRadical prostatectomy, moderately hypofractionated external beam radiotherapy, five-fraction stereotactic radiotherapy or brachytherapy, without hormone therapy.
Robotic & minimally invasive surgeryHypofractionated radiotherapySBRT / SABR (stereotactic radiotherapy)BrachytherapyCHHiPPACE-B
71

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.